Topical skin preparation composition containing taurine crystals with beneficial ingredients

Abstract

It provides a new means of delivering useful ingredients into the skin. A skin external preparation composition characterized by containing microneedle-shaped crystals of taurine containing a useful component in the crystal; a method for producing microneedle-shaped crystals of taurine containing a useful component in the crystal, comprising a process of growing crystals in an environment in which an aqueous solution (A) in which taurine is dissolved is mixed or contacted with a liquid substance (B) in which taurine is low, wherein the useful component is dissolved or dispersed in the aqueous solution (A) or the liquid substance (B), and thus the useful component is included in the crystals as the crystals grow.

Description

Technology Field

[0001] The present invention relates to a topical skin composition incorporating taurine crystals containing a useful ingredient. It relates to a technique for introducing a useful ingredient during taurine recrystallization. Background Technology

[0002] Taurine is a compound with the chemical name 2-aminoethanesulfonic acid and is the most abundant sulfur-containing free amino acid found in living cells. Although taurine is different from the amino acids that make up proteins and is known to act like vitamins or hormones, or to exert various pharmacological effects including those on the brain, nervous system, circulatory system, and hepatobiliary system, it has recently been known to play an important role in skin moisturization.

[0003] As a method for producing taurine, a number of production methods are known, such as extraction from marine products or multiple organic synthesis methods. For example, Patent Document 1 describes a method for obtaining taurine with high purity, and Patent Document 2 describes a method for obtaining taurine with high yield.

[0004] As a technique for purifying taurine, Patent Document 3 describes a method for purifying taurine in which a solution containing taurine and an inorganic salt is brought into contact with a porous solid material exhibiting a molecular sieve effect, thereby adsorbing taurine onto the porous solid material to separate it from the inorganic salt, and subsequently using an organic solvent that may contain water to detach the taurine adsorbed onto the porous solid material. Furthermore, as a means for purifying taurine with high yield, a technique of performing crystallization by adding alcohol is known in the past. That is, when purifying taurine from a hot water or hot water extraction solution of a natural product (such as aquatic products) or a solution from the end of a synthesis reaction, taurine crystals are precipitated in an aqueous alcohol solution, and final taurine crystals are obtained by filtration and drying. Patent Document 4 describes a method for purifying taurine in which impurities are separated or removed by adding alcohol to a taurine-containing reaction solution obtained through a manufacturing process. As a method for purifying the obtained crystal, Patent Document 5 describes a method for purifying taurine in which the crystal precipitated by crystal is separated from the crystal mother liquor, the crystal is treated with an aqueous alcohol solution containing hydrochloric acid, and then subsequently treated with an aqueous alcohol solution not containing hydrochloric acid.

[0005] On the other hand, regarding the technology of incorporating other components into crystals, research has been conducted to use them while ensuring that each component can be stabilized, for components such as vitamins, amino acids, and peptides, which are unstable in aqueous solutions, easily decomposed by oxidation or temperature, and difficult to stably combine. Patent Document 6 indicates that when calcium pantothenate and ascorbic acid are crystallized and mixed, the stability is improved compared to when they are mixed with calcium pantothenate that has not been crystallized. Furthermore, Patent Document 7 describes a method for obtaining a stable liquid formulation by adding water-soluble vitamins in a crystalline state to edible oils such as sunflower oil, corn oil, and cottonseed oil. Additionally, Patent Document 8 describes a lipstick composition containing a crystalline vitamin B3 compound. Prior art literature

[0006] Japanese Patent Publication No. 2021-172652 Japanese Patent Publication No. 2021-063060 Japanese Patent Publication No. 2005-232026 Japanese Patent Publication No. Hei 06-192209 Japanese Patent Publication No. Hei 07-017943 Japanese Patent Publication No. 2005-325080 Japanese Patent Publication No. 2004-500392 Japanese Patent Publication No. 2002-536391 The problem to be solved

[0007] While manufacturing and purification methods for obtaining taurine crystals with high purity and high yield are known, conversely, intentionally incorporating other active ingredients or skin-beneficial ingredients into taurine crystals has not been known until now.

[0008] Furthermore, regarding the technology of incorporating other components into crystals, the composition used in such technology is a mixture of powders in the absence of water or a composition dispersed in oil, and its use is limited to non-aqueous systems.

[0009] If useful organic compounds, peptides, pigments, etc., can be stably contained within water-soluble crystals, it becomes possible to color the crystals or stably incorporate useful components into various formulations. The objective of the present invention is to provide a new means of delivering useful components into the skin. means of solving the problem

[0010] The inventors have discovered, through repeated research, that by adding an aqueous solution of dissolved taurine to a water-soluble organic solvent such as an alcohol or polyol, which has low taurine solubility, or by slowly injecting the water-soluble organic solvent into the aqueous solution to form an interface separated into two phases of the aqueous solution of taurine and the water-soluble organic solvent, it is possible to produce fine needle-shaped crystals of taurine by creating a state of extremely low taurine solubility and proceeding with recrystallization therefrom, and that hollow crystals are formed during recrystallization. During this recrystallization, it is possible to produce fine needle-shaped crystals of taurine in which useful components, such as vitamins or pigments, are supported on the crystal surface or contained in the hollow portion by dissolving or dispersing useful components in either the aqueous solution of taurine or the water-soluble organic solvent used, or both. In addition, it was discovered that in a topical skin composition containing the obtained crystals, it is possible to provide a formulation that has no rough texture of the crystals and imparts a soft, powdery sensation of fine needle-like crystals.

[0011] The present invention is as described below.

[0012] [1] A skin external preparation composition characterized by containing fine needle-shaped crystals of taurine containing a useful component in the crystal.

[0013] [2] A skin external preparation composition described in [1], characterized by containing at least partially dispersed fine needle-shaped crystals of the above taurine.

[0014] [3] A skin external preparation composition described in [1] or [2], characterized by having a space inside the microacicular crystals of the above taurine, and containing a useful ingredient within the said space.

[0015] [4] A skin external application composition described in [3], characterized in that the internal space volume of the microacicular crystals of the taurine occupies 0.001% to 30% of the volume of the taurine crystals.

[0016] [5] A skin external preparation composition as described in any one of [1] to [4], wherein the thickness of the fine needle-shaped crystals of the taurine is 150 micrometers or less and the length is 3000 micrometers or less.

[0017] [6] A skin external preparation composition as described in any one of [1] to [5], characterized in that the above useful ingredient is one or more selected from the group consisting of vitamins and vitamin derivatives, hydroquinone and its derivatives, whitening ingredients, anti-inflammatory ingredients, antioxidant ingredients, blood circulation promoting ingredients, cell revitalizing ingredients, coenzymes and their intermediate metabolites, sugars, plant extract ingredients, peptides, proteins, and pigments.

[0018] [7] A skin external preparation composition as described in any one of [1] to [6], characterized in that the inclusion rate of the useful component in the fine needle-shaped crystals of the taurine is 0.001% to 30%.

[0019] [8] Additionally, a skin external use composition described in any one of [1] to [7], wherein a useful ingredient is dissolved or dispersed in the medium of the skin external use composition.

[0020] [9] A method for producing microneedle-shaped crystals of taurine containing a useful component in the crystal, comprising a process of growing crystals in an environment in which an aqueous solution (A) in which taurine is dissolved is mixed or contacted with a liquid substance (B) in which taurine is less soluble, wherein the useful component is dissolved or dispersed in the aqueous solution (A) or the liquid substance (B), and the useful component is included in the crystal as the crystal grows.

[0021]

[10] A manufacturing method described in [9], characterized in that the above liquid substance (B) is a water-soluble organic solvent.

[0022]

[11] The above water-soluble organic solvent is selected from the group consisting of ethanol, isopropyl alcohol, ethylene glycol, 1,2-propanediol, 1,3-propanediol, 1,2-butanediol, 1,3-butanediol, isoprene glycol, diethylene glycol, dipropylene glycol, glycerin, diglycerin, 1,2-pentanediol, 1,2-hexanediol, cyclohexylglycerin, and n-hexylglycerin.

[0023] A manufacturing method described in

[10] characterized by being of one or more types.

[0024]

[12] A method of manufacturing as described in any one of [9] to

[11] , characterized in that the concentration of the above useful component is 0.001 mass% or more in the above aqueous solution (A) or in the above liquid substance (B).

[0025]

[13] A manufacturing method described in any one of [9] to

[12] , characterized in that the concentration of taurine in the above aqueous solution (A) is 3 to 28 mass%.

[0026]

[14] A manufacturing method described in any one of [9] to

[13] , characterized in that the liquid substance (B) is 50 mass% or less with respect to the total amount of the aqueous solution (A).

[0027]

[15] A method for preparing a topical skin composition containing microacicular crystals of taurine containing a useful component in the crystal, comprising the following process:

[0028] A process for growing crystals in an environment in which an aqueous solution (A) in which taurine is dissolved is mixed or contacted with a liquid substance (B) in which taurine is less soluble, wherein a useful component is dissolved or dispersed in the aqueous solution (A) or the liquid substance (B), and the useful component is included in the crystal as a result of crystal growth, and

[0029] A manufacturing method comprising a process of incorporating microneedle-shaped crystals of taurine containing useful components in the crystals, obtained from the above crystal growth process, into a topical skin preparation composition.

[0030]

[16] A manufacturing method described in

[15] characterized in that the concentration of the above useful component is 0.001 mass% or more in the above aqueous solution (A) or in the above liquid substance (B).

[0031]

[17] A method of manufacturing as described in

[15] or

[16] , characterized in that the concentration of taurine in the above aqueous solution (A) is 3 to 28 mass%.

[0032]

[18] A manufacturing method described in any one of

[15] to

[17] , characterized in that the liquid substance (B) is 50 mass% or less with respect to the total amount of the aqueous solution (A).

[0033]

[19] A method of manufacturing as described in any one of

[15] to

[18] , wherein the above liquid substance (B) is a water-soluble organic solvent, and the water-soluble organic solvent is one or more selected from the group consisting of ethanol, isopropyl alcohol, ethylene glycol, 1,2-propanediol, 1,3-propanediol, 1,2-butanediol, 1,3-butanediol, isoprene glycol, diethylene glycol, dipropylene glycol, glycerin, diglycerin, 1,2-pentanediol, 1,2-hexanediol, cyclohexylglycerin, and n-hexylglycerin. Effects of the invention

[0034] The external skin composition of the present invention contains taurine micro-needle crystals containing a useful ingredient, so the useful ingredient can be stably retained within the composition. Since the taurine crystals in the present invention are formed into micro-needle crystals by recrystallization, it is possible to pierce the crystals into the stratum corneum without feeling the rough texture of the crystals during use, directly transfer the useful ingredient into the skin, and then supply the included ingredient into the skin by dissolving the crystals in the moisture inside the skin. Brief explanation of the drawing

[0035] Figure 1 is the X-ray diffraction pattern of the taurine microacoustic crystal obtained in Example 14. The upper graph is the astaxanthin-containing taurine microacoustic crystal, and the lower graph is the taurine microacoustic crystal. Figure 2 is an optical microscope image of taurine microneedle crystals obtained in Example 3. Figure 3 is an optical microscope image of raw taurine crystals. Figure 4 is an optical microscope image (magnification 50x) of taurine microneedle crystals obtained in Example 17. Figure 5 is a micrograph (under fluorescence, magnification 50x) of taurine microneedle crystals obtained in Example 17. Figure 6 is an optical microscope image (magnification 200x) of taurine microneedle crystals obtained in Example 17. Figure 7 is a micrograph (under fluorescence, magnification 200x) of taurine microneedle crystals obtained in Example 17. Figure 8 is a fluorescent photograph (magnification 50x) of a cross-section of the skin 5 minutes after application. Figure 9 is a fluorescent photograph (magnification 50x) of a cross-section of the skin 30 minutes after application. Figure 10 is a graph showing the measurement results of Example 19 and Comparative Example 7. Specific details for implementing the invention

[0036] The topical skin composition according to the present invention contains microacoustic crystals of taurine containing a useful component within the crystals. In the topical skin composition, it is preferable that the microacoustic crystals of taurine are contained in at least a partially dispersed manner.

[0037] The above-mentioned taurine microneedle crystals can be manufactured by creating a state of extremely low solubility of taurine and proceeding with recrystallization (crystal growth) therefrom, by mixing an aqueous solution (A) in which taurine is dissolved with a liquid substance (B) in which taurine is low solubility (e.g., a water-soluble organic solvent), or by bringing the aqueous solution (A) in which taurine is dissolved with a liquid substance (B) in which taurine is low solubility (e.g., forming an interface by slowly injecting the liquid substance (B) into the aqueous solution (A). The obtained taurine microneedle crystals have a controlled crystal form. Additionally, when manufacturing the crystals, a hollow portion is formed within the taurine microneedle crystals, and this hollow portion is defined as the spatial volume.

[0038] Accordingly, the microacicular crystals of taurine have spaces within the microacicular crystals of taurine. It is preferable that the volume of the spaces of the microacicular crystals of taurine occupies 0.001% to 30% of the volume of the taurine crystals, and more preferable that it occupies 0.1% to 30%. Here, the size of the volume of the spaces of the microacicular crystals of taurine is calculated by interpreting microscopic images of the crystals.

[0039] The taurine microneedle crystal containing a useful component in the crystal can be prepared by dissolving or dispersing a useful component (any organic compound component, peptide, protein, or pigment, etc.) in an aqueous solution (A) or a liquid substance (B) during the recrystallization of the taurine. It can also be prepared by incorporating or supporting the useful component during the recrystallization. Here, incorporation refers to at least one of the following: entering into the taurine crystal lattice or containing the useful component in the hollow portion (space) of the taurine crystal. In the former case, the lattice constant increases in correspondence with the expansion of the taurine crystal. In the latter case, the lattice constant does not expand due to incorporation. Support refers to adsorbing or binding to the surface of the taurine crystal. In the present invention, a taurine microneedle crystal containing or supporting a useful component, that is, a taurine microneedle crystal containing a useful component in the crystal, may be referred to as a taurine microneedle crystal containing a useful component. It is desirable that the fine needle-like crystals of taurine have spaces, and that useful components are contained within those spaces.

[0040] The taurine used as a raw material in the present invention is not specifically limited to any that has been conventionally used in pharmaceuticals, quasi-pharmaceuticals, or cosmetics, and includes both synthetic products and extracts from natural products.

[0041] The microcrystals of taurine in the present invention are needle-shaped crystals, but may also be columnar crystals. Here, a needle-shaped crystal refers to a shape in which the long diameter of the crystal is three times or more the short diameter, and a columnar crystal refers to a shape in which the long diameter of the crystal is less than three times the short diameter. The micro needle-shaped or columnar crystals of taurine in the present invention are crystal forms that can be distinguished from the bulk crystals of raw taurine by microscopic observation. An example of a micro needle-shaped crystal is shown in FIG. 2, and an example of a bulk crystal is shown in FIG. 3. Hereinafter, the taurine recrystallized in the present invention will be referred to as taurine micro needle-shaped crystals.

[0042] The size of the taurine microneedle crystals is preferably such that, when used in a topical skin preparation composition, it does not leave a rough texture and provides a soft, powdery finish. It is more preferable that the thickness is 150 micrometers or less and the length is 3000 micrometers or less, more preferable that the thickness is 5 to 150 micrometers and the length is 100 to 3000 micrometers, even more preferable that the thickness is 10 to 100 micrometers and the length is 100 to 2000 micrometers, and most preferable that the thickness is 10 to 60 micrometers and the length is 150 to 2000 micrometers.

[0043] Here, thickness refers to the short diameter of the crystal, and length refers to the long diameter of the crystal. The thickness and length of the crystal can be measured using a digital microscope (e.g., the "Digital Microscope VHX-7000" manufactured by Keyence Co., Ltd.).

[0044] Crystalline forms with a thickness exceeding 150 micrometers and a length exceeding 3000 micrometers (e.g., taurine crystals and taurine crystalline powders commercially available as raw materials) are undesirable because they leave a gritty foreign sensation on the skin when applied.

[0045] In the present invention, among the fine needle-shaped crystals of taurine, particulate crystals with a thickness of less than 5 micrometers or a length of less than 100 micrometers may be included, but it is particularly preferable not to include crystals with a thickness exceeding 150 micrometers. In the present invention, conditions for recrystallization can be set so that needle-shaped crystals with a thickness exceeding 150 micrometers are not formed.

[0046] Specific recrystallization (crystal growth) conditions are a process of growing crystals in an environment in which an aqueous solution (A) in which taurine is dissolved is mixed or brought into contact with a liquid substance (B) in which taurine has low solubility.

[0047] Examples of liquid substances (B) with low solubility of taurine used for recrystallization (crystal growth) include organic solvents, which are not particularly limited but include, for example, polar organic solvents such as acetone, methyl ethyl ketone, dimethyl sulfoxide, dimethylformamide, ethyl acetate, isopropyl myristate, methylheptyl laurate, and jojoba oil; non-polar organic solvents such as dodecane, isododecane, liquid paraffin, squalane, hydrogenated polyisobutene, and olefin oligomers; alcohols such as ethanol and 1-propanol; polyhydric alcohols such as 1,3-butanediol, glycerin, and 1,2-pentanediol. Among them, in terms of the high effect of lowering the solubility of taurine by addition, the liquid substance (B) is preferably a liquid substance (water-soluble organic solvent) having a solubility in water of 1 mass% or more at 25°C, and specifically, it is preferably ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, ethylene glycol, diethylene glycol, 1,2-propanediol, 1,3-propanediol, 1,2-butanediol, 1,3-butanediol, isoprene glycol, diethylene glycol, dipropylene glycol, glycerin, diglycerin, 1,2-pentanediol, 1,2-hexanediol, acetone, methyl ethyl ketone, dimethyl sulfoxide, dimethylformamide, cyclohexylglycerin, or n-hexylglycerin. In terms of using the obtained microneedle crystals as a component of a topical skin preparation, the liquid substance (B) is most preferably ethanol, isopropyl alcohol, ethylene glycol, 1,2-propanediol, 1,3-propanediol, 1,2-butanediol, 1,3-butanediol, isoprene glycol, diethylene glycol, dipropylene glycol, glycerin, diglycerin, 1,2-pentanediol, 1,2-hexanediol, cyclohexylglycerin, or n-hexylglycerin. One of these or a mixture of two or more solvents may be used.

[0048] If the liquid substance (B) is not used, the crystalline form does not become fine needle-shaped crystals, and when incorporated into a topical skin composition, it results in a gritty texture, which is undesirable.

[0049] Regarding the concentration of taurine in the aqueous solution (A) in which taurine is dissolved for use in recrystallization, it is preferable to have 3 mass% or more from the perspective of forming fine needle-shaped crystals when mixed with a solvent with low solubility of taurine, and 28 mass% or less from the perspective of the solubility of taurine in water. If it is less than 3 mass%, crystals do not precipitate unless 100 mass% or more of the liquid substance (B) is added to the aqueous solution (A), and a sufficient amount of crystals is not obtained, so it is not practical in terms of cost and yield. If it exceeds 28 mass%, the recrystallization process is not practical because it becomes difficult to dissolve taurine even when heated to 80°C or higher. In this regard, the concentration of taurine in the aqueous solution (A) in which taurine is dissolved is preferably 5 to 20 mass%, more preferably 6 to 18 mass%, and most preferably 7 to 15 mass%.

[0050] In the aqueous solution (A) in which taurine is dissolved for recrystallization, one or more water-soluble organic solvents with low solubility of taurine may be added as a liquid substance (B) for the purpose of lowering the saturation concentration. In this case, water-soluble organic solvents such as glycerin, 1,3-propanediol, ethanol, isopropyl alcohol, ethylene glycol, 1,2-propanediol, 1,2-butanediol, 1,3-butanediol, isoprene glycol, diethylene glycol, dipropylene glycol, diglycerin, 1,2-pentanediol, 1,2-hexanediol, cyclohexylglycerin, n-hexylglycerin, etc. are preferred. The concentration of the liquid substance (B) (water-soluble organic solvent) is preferably 50 mass% or less, more preferably 30 mass% or less, and most preferably 25 mass% or less with respect to the total amount of the aqueous solution (A). If it exceeds 50 mass%, the solubility of taurine becomes too low, and since a sufficient amount of crystals cannot be obtained, it is not realistic in terms of cost and yield.

[0051] In the present invention, the useful components included in the microacoustic crystals of taurine are not particularly limited. Examples of the useful components include vitamins and vitamin derivatives, hydroquinone and its derivatives, whitening components, anti-inflammatory components, antioxidant components, blood circulation promoting components, cell revitalization components, coenzymes and their intermediate metabolites, sugars, plant extract components, peptides, proteins, and pigments.

[0052] The above vitamins and vitamin derivatives, hydroquinone and its derivatives, whitening ingredients, anti-inflammatory ingredients, antioxidant ingredients, blood circulation promoting ingredients, cell revitalization ingredients, coenzymes and their intermediate metabolites include, for example, nicotinamide, glycyrrhizinate, tranexamic acid, L-ascorbic acid-2-glucoside, sodium ascorbyl phosphate, glyceryl ascorbic acid, bis-glyceryl ascorbic acid, 3-glyceryl ascorbic acid, hexyl 3-glyceryl ascorbic acid, myristyl 3-glyceryl ascorbic acid, 3-lauryl glyceryl ascorbic acid, arbutin, kojic acid, allantoin, cyanocobalamin, riboflavin, pyridoxine salt, glucosylhesperidin, tetrahexyl decanoate ascorbyl, 3-0-ethylascorbic acid, tocopherol acetate, It includes copper chlorophyllin sodium, folic acid, hydroquinone, ubiquinone, pyrroloquinolinequinone, topaquinone, tryptophan-tryptophylquinone, lysine tyrosylquinone, cystenyl-tryptophanquinone, thiamine diphosphate, pantothenic acid, biotin, adenosine triphosphate, uridine diphosphate glucose, ribonucleotide, deoxynucleotide, nicotinamide mononucleotide, β-carotene, and astaxanthin.

[0053] The above sugars include D-glycerylaldehyde, dihydroxyacetone, D-erythose, D-erythrulose, D-threose, erythritol, L-arabinose, D-xylose, L-lixose, D-arabinose, D-ribose, D-ribulose, D-xylose, L-xylose, D-glucose, D-talose, D-psicose, D-galactose, D-fructose, L-galactose, L-mannose, D-tagatose, aldoheptose, heptose, octulose, etc., 2-deoxy-D-ribose, 6-deoxy-L-galactose, 6-deoxy-L-mannose, D-glucosamine, D-galactosamine, sialic acid, aminouronic acid, muramic acid, etc., D-glucuronic acid, D-mannuronic acid, Includes L-gluronic acid, D-galacturonic acid, L-iduronic acid, sorbitol, sucrose, mannitol, fructose, raffinose, maltose, xylitol, maltitol, palatinose, arabinose, maltotriose, sucrose, erythritol, glucose, starch hydrolysate, guntianos, umbelliferose, lactose, plantose, isolychnoses, trehalose, lignoses, umbilisin, stachyose berbascose, hydrolyzed hydrogenated starch, and glyceryl glucoside.

[0054] The above plant extract ingredients include, for example, Korean ginseng, Angelica gigas, arnica, ginkgo biloba, fennel, turmeric, mint, Dutch oak, chamomile, Roman chamomile, carrot, gentian, burdock, rice, hawthorn, shiitake mushroom, ginger, European hawthorn, European juniper, Cnidium officinale, Angelica gigas, thyme, clove, dried tangerine peel, chili pepper, Angelica gigas, peach kernel, spruce, ginseng, garlic, butcher's broom, grape, peony, horse chestnut, melissa, yuzu, Coix lacryma-jobi, green tea, rosemary, rose hip, dried tangerine peel, Angelica gigas, spruce, peach, apricot, walnut, corn, golden chamomile, ichthamol, canthalis tincture, and cephalanthin.

[0055] The above peptides include (arginine / lysine) polypeptide, 3-ascorbyl carbonyl dipeptide, acetylcyclohexapeptide, acetyl tetrapeptide, acetyl tetrapeptide, acetyl tetrapeptide, acetyl tetrapeptide, acetyl tetrapeptide, acetyl hexapeptide, acetyl hexapeptide, acetyl heptapeptide, acetyl pentapeptide, oligopeptide, caffeoyl tripeptide, capryloyl dipeptide, capryloyl synthetic human nonapeptide, dipeptide, diacetate dipeptide diaminobutyroylbenzylamide, decapeptide, tetrapeptide, trifluoroacetyl tripeptide, tripeptide, tripeptide-1 copper, nonapeptide, palmitate heptapeptide, palmitoyl octapeptide, palmitoyl oligopeptide, palmitoyl dipeptide, palmitoyl dipeptide-5 diaminohydroxybutyric acid, It includes palmitoyl dipeptide-5-diaminobutyroylhydroxyleonine, palmitoyl tetrapeptide, human recombinant oligopeptide, human recombinant polypeptide, synthetic human nonapeptide, N-prolyl palmitoyl tripeptide acetate, and hexanoyl dipeptide-3-norleucine acetate.

[0056] The above proteins include almond protein, rice protein, wheat protein, wheat germ protein, soybean protein, corn gluten protein, and nacre protein.

[0057] The above pigments include natural pigments and synthetic pigments, and natural pigments include, for example, gardenia yellow pigment, safflower yellow pigment, turmeric pigment, red yeast rice yellow pigment, marigold pigment, red yeast rice pigment, gardenia red pigment, safflower red pigment, tomato pigment, cochineal pigment, perilla pigment, red cabbage pigment, red radish pigment, purple sweet potato pigment, grape skin pigment, cacao pigment, caramel pigment, gardenia blue pigment, etc., and synthetic pigments include, for example, organic pigments such as Red 201, Red 202, Red 204, Red 205, Red 220, Red 226, Red 228, Red 405, Orange 203, Orange 204, Yellow 205, Yellow 401, and Blue 404, Red 3, Red 104, Red 106, Red 227, Red 230, Red Examples include No. 401, Red No. 505, Orange No. 205, Yellow No. 4, Yellow No. 5, Yellow No. 202, Yellow No. 203, Green No. 3, and Blue No. 1.

[0058] It is possible to include one or more of the above useful components in the fine needle-shaped crystals of taurine.

[0059] The above useful ingredients are not limited to water-soluble ingredients but may also be oil-soluble ingredients. Furthermore, even ingredients that are prone to oxidation, particularly those that could not be incorporated previously due to changes in odor or discoloration over time, can be incorporated by incorporating them into the taurine microneedle crystals, thereby enabling their stable presence. Additionally, since the taurine microneedle crystals in the topical skin composition dissolve and the contained ingredients dissolve after the composition is applied to the skin, the contained ingredients can be applied to the skin in a fresh state. Furthermore, by incorporating bio-derived ingredients such as high molecular weight polysaccharides, peptides like glucose factor, and proteins that are difficult to penetrate the skin into the taurine crystals, the needle crystals in the composition can be directly punctured into the skin to facilitate penetration.

[0060] The amount of the useful component included can be expressed as a percentage of the amount of the useful component in the total weight of the crystal. The percentage of the useful component in the fine needle-shaped crystals of taurine is preferably 0.001 to 30 mass%, more preferably 0.001 to 25 mass%, and most preferably 0.001 to 20 mass%. If the percentage is less than 0.001 mass%, it is not desirable because the effect of the useful component included is not sufficiently obtained.

[0061] In order to suitably obtain fine needle-shaped crystals of taurine having the above-described inclusion ratio, when producing fine needle-shaped crystals of taurine, it is preferable to use the useful component in a state where it is dissolved or dispersed in an aqueous solution (A) in which taurine is dissolved or in a liquid substance (B) with low solubility of taurine. The concentration of the useful component is preferably 0.001 mass% or more in the aqueous solution (A) or the liquid substance (B) in terms of the amount of inclusion component introduced into the taurine crystals. If it is less than 0.001 mass%, it is not desirable because it is impossible to confirm that the inclusion component is contained therein. Furthermore, the upper limit of the concentration of the useful component is not particularly limited.

[0062] Microneedle crystals of taurine containing a useful component may be incorporated into a topical skin composition after being filtered and dried, or the solution from which the crystals were precipitated may be incorporated as is. Furthermore, the useful component may not only be present in the microneedle crystals of taurine but may also be dissolved or dispersed in the medium of the topical skin composition. In that case, the useful component in the microneedle crystals of taurine and the useful component dissolved or dispersed in the medium of the topical skin composition may be the same or different.

[0063] The external skin composition of the present invention can be used primarily as an external skin composition for cosmetics or quasi-drugs. The formulation of the external skin composition of the present invention is not particularly limited, but examples include liquids, lotions, cosmetic emulsions, fluids, creams, aqueous gels, ointments, etc. These formulations can be prepared by conventional methods.

[0064] For liquids, lotions, emulsions, creams, and aqueous gels, it is possible to formulate the preparation while maintaining taurine microneedle crystals containing useful ingredients by maintaining the taurine concentration in the aqueous phase above the saturation concentration.

[0065] For cosmetic emulsions and ointments, it is possible to formulate taurine microneedle crystals containing useful ingredients by incorporating filtered and dried materials.

[0066] In addition, the skin external preparation composition of the present invention may appropriately include one or more ingredients commonly used in formulations such as cosmetics, quasi-drugs, and external medicines, within a range that does not impair the effects of the present invention, namely water, emulsions, surfactants, gelling agents, powders, alcohols, water-soluble polymers, film-forming agents, resins, UV protection agents, inclusion compounds, antibacterial agents, fragrances, deodorizers, salts, pH adjusters, fresheners, animal or microbial extracts, plant extracts, blood circulation promoters, astringents, anti-seborrheic agents, whitening agents, anti-inflammatory agents, moisturizers, anti-glycation agents, keratolytic agents, enzymes, hormones, vitamins, etc.

[0067] The water included in the external skin preparation composition of the present invention is not particularly limited and, for example, purified water, ion-exchanged water, tap water, etc. may be used.

[0068] Examples of water-soluble alcohols include, for instance, lower alcohols, polyhydric alcohols, polyhydric alcohol polymers, dihydric alcohol alkyl ethers, dihydric alcohol alkyl ethers, dihydric alcohol ether esters, glycerin monoalkyl ethers, sugar alcohols, monosaccharides, oligosaccharides, polysaccharides, and their derivatives.

[0069] Examples of lower alcohols include ethanol, propanol, isopropanol, isobutyl alcohol, t-butyl alcohol, etc.

[0070] As polyhydric alcohols, for example, dihydric alcohols (e.g., dipropylene glycol, 1,3-butylene glycol, ethylene glycol, trimethylene glycol, 1,2-butylene glycol, tetramethylene glycol, 2,3-butylene glycol, pentamethylene glycol, 2-butene-1,4-diol, hexylene glycol, octylene glycol, etc.), trihydric alcohols (e.g., glycerin, trimethylolpropane, etc.), tetrahydric alcohols (e.g., diglycerin, pentaerythritol such as 1,2,6-hexanetriol, etc.), pentahydric alcohols (e.g., xylitol, triglycerin, etc.), hexahydric alcohols (e.g., sorbitol, mannitol, etc.), polyhydric alcohol polymers (e.g., diethylene glycol, dipropylene glycol-triethylene glycol, polypropylene glycol, tetraethylene glycol, diglycerin-triglycerin, tetraglycerin, polyglycerin, etc.), and dihydric Alcohol alkyl ethers (e.g., ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, ethylene glycol monophenyl ether, ethylene glycol monohexyl ether, ethylene glycol mono2-methylhexyl ether, ethylene glycol isoamyl ether, ethylene glycol benzyl ether, ethylene glycol isopropyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, ethylene glycol dibutyl ether, etc.), dihydric alcohol alkyl ethers (e.g., diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol dimethyl ether, diethylene glycol diethyl ether, diethylene glycol butyl ether, diethylene glycol methyl ethyl ether, triethylene glycol monomethyl ether, triethylene glycol monoethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monobutyl ether, Propylene glycol isopropyl ether, dipropylene glycol methyl ether, dipropylene glycol ethyl ether, dipropylene glycol butyl ether, etc.), dihydric alcohol ether esters (e.g., ethylene glycol monomethyl ether acetate, ethylene glycol monoethyl ether acetate, ethylene glycol monobutyl ether acetate, ethylene glycol monophenyl ether acetate, ethylene glycol diadiate, ethylene glycol disuccinate,Diethylene glycol monoethyl ether acetate, diethylene glycol monobutyl ether acetate, propylene glycol monomethyl ether acetate, propylene glycol monoethyl ether acetate, propylene glycol monopropyl ether acetate, propylene glycol monophenyl ether acetate, etc.), glycerin monoalkyl ethers (e.g., xyl alcohol, celakyl alcohol, batyl alcohol, etc.), sugar alcohols (e.g., maltotriose, mannitol, sucrose, erythritol, glucose, fructose, starch hydrolyzed sugars, maltose, starch hydrolyzed sugar reducing alcohols, etc.), glycolides, tetrahydrofurfuryl alcohol, POE-tetrahydrofurfuryl alcohol, POP-butyl ether, POP·POE-butyl ether tripolyoxypropylene glycerin ether, POP-glycerin ether, POP-glycerin ether phosphoric acid, POP·POE-pentanerythritol ether, Examples include polyglycerin, etc.

[0071] As monosaccharides, for example, trioses (e.g., D-glycerylaldehyde, dihydroxyacetone, etc.), tetraoses (e.g., D-erythose, D-erythrulose, D-threose, erythritol, etc.), pentoses (e.g., L-arabinose, D-xylose, L-lixose, D-arabinose, D-ribose, D-ribulose, D-xylose, L-xylose, etc.), hexoses (e.g., D-glucose, D-talose, D-psicose, D-galactose, D-fructose, L-galactose, L-mannose, D-tagatose, etc.), heptoses (e.g., aldoheptose, heptose, etc.), octoses (e.g., octulose, etc.), deoxysaccharides (e.g., 2-deoxy-D-ribose, 6-deoxy-L-galactose, Examples include 6-deoxy-L-mannose, etc.), amino sugars (e.g., D-glucosamine, D-galactosamine, sialic acid, aminouronic acid, muramic acid, etc.), uronic acids (e.g., D-glucuronic acid, D-mannuronic acid, L-glucuronic acid, D-galacturonic acid, L-iduronic acid, etc.).

[0072] Examples of oligosaccharides include sucrose, gentianose, umbeliferose, lactose, plantose, isolichnose, α,α-trehalose, raffinose, ricnose, umbilisin, stachyose berbascoose, etc.

[0073] Examples of polysaccharides include, for instance, cellulose, quince seed, starch, galactan, dermatan sulfate, glycogen, gum arabic, heparan sulfate-tragacanth gum, keratan sulfate, chondroitin, xanthan gum, guar gum, dextran, keratosulfate, locust bean gum, succinoglucan, etc.

[0074] Examples of anti-inflammatory agents include, for instance, ingredients derived from plants, allantoin and its derivatives, glycyrrhetinic acid and its derivatives, glycyrrhizic acid and its salts or derivatives, salicylic acid derivatives, aminocaproic acid, azulene and its derivatives.

[0075] Examples of gelling agents (thickening agents) include gum arabic, carrageenan, karaya gum, tragacanth gum, carob gum, quince seed (marmelo), casein, dextrin, gelatin, sodium pectinate, sodium arginate, methylcellulose, ethylcellulose, CMC, hydroxyethylcellulose, hydroxypropylcellulose, PVA, PVM, PVP, sodium polyacrylate, carboxyvinyl polymer, locust bean gum, guar gum, tamarind gum, cellulose dialkyldimethylammonium sulfate, xanthan gum, magnesium aluminum silicate, bentonite, hectorite, A1Mg silicate (bi gum), raponite, anhydrous silica, etc.

[0076] Examples of natural water-soluble polymers include plant-based polymers (e.g., gum arabic, tragacanth gum, galactan, guar gum, carob gum, karaya gum, carrageenan, pectin, agar, quince seed (marmelo), arge colloid (brown algae extract), starch (rice, corn, potato, wheat), glycyrrhizic acid), microbial-based polymers (e.g., xanthan gum, dextran, succinoglucan, pullulan, etc.), and animal-based polymers (e.g., collagen, casein, albumin, gelatin, etc.).

[0077] Examples of semi-synthetic water-soluble polymers include starch-based polymers (e.g., carboxymethyl starch, methylhydroxypropyl starch, etc.), cellulose-based polymers (methylcellulose, ethylcellulose, methylhydroxypropylcellulose, hydroxyethylcellulose, sodium cellulose sulfate, hydroxypropylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, crystalline cellulose, cellulose powder, etc.), and alginate-based polymers (e.g., sodium alginate, propylene glycol alginate ester, etc.).

[0078] Examples of water-soluble polymers for synthesis include vinyl polymers (e.g., polyvinyl alcohol, polyvinylmethyl ether, polyvinylpyrrolidone, carboxyvinyl polymer, etc.), polyoxyethylene polymers (e.g., polyethylene glycol 20,000, 40,000, 60,000, etc.), acrylic polymers (e.g., sodium polyacrylate, polyethyl acrylate, polyacrylamide, etc.), polyethyleneimine, cationic polymers, etc.

[0079] Examples of moisturizers include chondroitin sulfate, hyaluronic acid, mucoitin sulfate, caronic acid, atelocollagen, cholesteryl-12-hydroxystearate, sodium lactate, bile salts, DL-pyrrolidone carboxylate, short-chain soluble collagen, diglycerin (EO) PO adduct, Rosa Roxburghie extract, yarrow extract, melilot extract, etc.

[0080] Examples of whitening agents (whitening ingredients) include, for instance, tranexamic acid, ascorbic acid and its salts, vitamin C derivatives such as sodium ascorbic acid phosphate ester, magnesium ascorbic acid phosphate ester, tetra2-hexyldecanoate ascorbyl, 2-O-ethylascorbic acid, 3-O-ethylascorbic acid, ascorbic acid glucoside, etc., arbutin, kojic acid, placenta, ellagic acid, nicotinamide, hydroquinone, linoleic acid and its derivatives.

[0081] Examples of keratolytic agents (keratolytic softening ingredients) include lactic acid, salicylic acid, gluconic acid, glycolic acid, citric acid, malic acid, fructic acid, phytic acid, urea, sulfur, etc.

[0082] Examples of anti-aging ingredients include hydrolyzed soy protein, retinoids (retinol and its derivatives, retinoic acid and retinal, etc.), kinetin, adenosine, NMN (nicotinamide mononucleotide), AMP (adenosine monophosphate), ADP (adenosine diphosphate), ATP (adenosine triphosphate), ursolic acid, turmeric extract, sphingosine derivatives, mevalonolactone, etc.

[0083] Examples of anti-glycation agents (anti-glycation components) include plant extracts such as Buddleja axillaris leaf extract, evening primrose oil, the fruit or juice of Amla or their extracts, L-arginine, L-lysine, hydrolyzed casein, hydrolyzable tannin, carnosine, etc.

[0084] Examples of blood circulation promoters (components with blood circulation-promoting effects) include, for instance, Korean ginseng, Angelica gigas, arnica, ginkgo biloba, fennel, mint, Dutch oak, chamomile, Roman chamomile, carrot, gentian, burdock, rice, hawthorn, shiitake mushroom, ginger, European hawthorn, European juniper, Cnidium officinale, Angelica dahurica, thyme, clove, dried tangerine peel, chili pepper, Angelica gigas, peach kernel, spruce, ginseng, garlic, butcher's broom, grape, peony, horse chestnut, melissa, yuzu, Coix lacryma-jobi, green tea, rosemary, rose hip, dried tangerine peel, Angelica gigas, spruce, peach, apricot, walnut, corn, golden chamomile, ichthamol, canthalis tincture, cephalanthin, etc., and components derived from plants: gamma oryzanol, nicotinic tocopherol, glucosyl hesperidin, etc.

[0085] Examples of polyphenols include flavonoid-based polyphenols such as curcominoids, flavanones, stilbenoids, polymethoxyflavonoids, flavonols, xanthonoids, chalcones, lignoids, flavanols, and isoflavones.

[0086] Examples of metal ion chelating agents include 1-hydroxyethane-1,1-diphosphonic acid, 1-hydroxyethane-1,1-diphosphonic acid tetrasodium salt, disodium edetate, trisodium edetate, tetrasodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid, phosphoric acid, citric acid, ascorbic acid, succinic acid, edetic acid, trisodium ethylenediaminehydroxyethyl triacetate, etc.

[0087] As a UV protective agent (water-soluble UV absorber), for example, benzophenone-based UV absorbers such as 2,4-dihydroxybenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, 2,2',4,4'-tetrahydroxybenzophenone, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonate, 4-phenylbenzophenone, 2-ethylhexyl-4'-phenyl-benzophenone-2-carboxylate, 2-hydroxy-4-n-octoxybenzophenone, 4-hydroxy-3-carboxybenzophenone, etc. Examples include benzimidazole-based ultraviolet absorbers such as phenylbenzimidazole-5-sulfonic acid and its salts, phenylene-bis-benzimidazole-tetrasulfonic acid and its salts, 3-(4'-methylbenzylidene)-d,l-campho, 3-benzylidene-d,l-campho, urocanic acid, urocanic acid ethyl ester, etc.

[0088] As for the powder (powder component), for example, inorganic powder (e.g., talc, kaolin, mica, sericite, muscovite, phlogopite, synthetic mica, red mica, biotite, vermiculite, magnesium carbonate, calcium carbonate, aluminum silicate, barium silicate, calcium silicate, magnesium silicate, strontium silicate, metal tungstate salts, magnesium, silica, zeolite, barium sulfate, calcined calcium sulfate (calcium sulfate), calcium phosphate, fluoroapatite, hydroxyapatite, ceramic powder, metal soap (e.g., zinc myristate, calcium palmitate, aluminum stearate), boron nitride, etc.), organic powder (e.g., polyamide resin powder (nylon powder), polyethylene powder, methyl polymethacrylate powder, polystyrene powder, copolymer resin powder of styrene and acrylic acid, benzoguanamine resin powder, Polytetrafluoroethylene powder, cellulose powder, etc.), inorganic white pigments (e.g., titanium dioxide, zinc oxide, etc.), inorganic red pigments (e.g., iron oxide (Bengala), iron titanate, etc.), inorganic brown pigments (e.g., γ-iron oxide, etc.), inorganic yellow pigments (e.g., iron sulfate, ochre, etc.), inorganic black pigments (e.g., black iron oxide, low-order titanium oxide, etc.), inorganic purple pigments (e.g., mango violet, cobalt violet, etc.), inorganic green pigments (e.g., chromium oxide, chromium hydroxide, cobalt titanate, etc.), inorganic blue pigments (e.g., ultramarine, indigo, etc.), pearl pigments (e.g., titanium-coated mica, titanium-coated bismuth oxychloride, titanium-coated talc, colored titanium-coated mica, bismuth oxychloride, irrinb, etc.), metal powder pigments (e.g. Organic pigments such as aluminum powder, copper powder, etc.), zirconium, barium, or aluminum lake (e.g., organic pigments such as Red 201, Red 202, Red 204, Red 205, Red 220, Red 226, Red 228, Red 405, Orange 203, Orange 204, Yellow 205, Yellow 401, and Blue 404, Red 3,Examples include Red 104, Red 106, Red 227, Red 230, Red 401, Red 505, Orange 205, Yellow 4, Yellow 5, Yellow 202, Yellow 203, Green 3, and Blue 1, etc.), and natural pigments (e.g., chlorophyll, β-carotene, etc.).

[0089] Examples of vitamins include vitamins A, B1, B2, B6, C, E and their derivatives, pantothenic acid and its derivatives, biotin, etc.

[0090] Examples of antioxidants include tocopherols, dibutylhydroxytoluene, butylhydroxyanisole, gallic acid esters, etc.

[0091] Examples of pH adjusting agents include buffers such as lactic acid-sodium lactate, citric acid-sodium citrate, and succinic acid-sodium succinate.

[0092] Examples of the above-mentioned emulsion (oil phase component) include liquid oils, solid oils, waxes, hydrocarbon oils, higher fatty acids, synthetic ester oils, silicone oils, etc., which are commonly used in cosmetics or quasi-drugs. These oil phase components and the above-mentioned aqueous components can be combined with a suitable surfactant to form a skin composition.

[0093] Examples of liquid oils include avocado oil, camellia oil, turtle oil, macadamia nut oil, corn oil, mink oil, olive oil, rapeseed oil, egg yolk oil, sesame oil, persic oil, wheat germ oil, camellia oil, castor oil, linseed oil, safflower oil, cottonseed oil, perilla oil, soybean oil, peanut oil, tea seed oil, tortoise oil, rice bran oil, paulownia oil, Japanese tung oil, jojoba oil, germ oil, triglycerin, etc.

[0094] Examples of solid fats include, for instance, cocoa butter, palm oil, sorghum, hydrogenated palm oil, palm oil, beef tallow, beef tallow, hydrogenated beef tallow, palm kernel oil, lard, beef bone fat, beeswax kernel oil, hydrogenated oil, beef horn fat, beeswax, hydrogenated castor oil, etc.

[0095] Examples of waxes include, for instance, beeswax, candelilla wax, cotton wax, carnauba wax, bayberry wax, pewter, light wax, montan wax, rice bran wax, lanolin, kapok wax, lanolin acetate, liquid lanolin, sugarcane wax, lanolin fatty acid isopropyl, hexyl laurate, reduced lanolin, jojoba wax, hard lanolin, shellac wax, polyoxyethylene lanolin alcohol ether, polyoxyethylene lanolin alcohol acetate, polyoxyethylene cholesterol ether, lanolin fatty acid polyethylene glycol, polyoxyethylene hydrogenated lanolin alcohol ether, cetyl palmitate, etc.

[0096] Examples of hydrocarbon oils include liquid paraffin, ozokerite, squalane, pristine, paraffin, ceresin, squalene, petroleum jelly, microcrystalline wax, etc.

[0097] Examples of high-grade fatty acids include lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, undecylenic acid, tol acid, linoleic acid, linoleic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), etc.

[0098] Examples of synthetic ester oils include cetyl octanoate, myristyl myristate, tri-2-ethylhexanoate glyceryl tetra-2-ethylhexanoate pentaerythritate, dioctyl succinate, and tripropylene glycol di-neopentanoate.

[0099] Examples of silicone oils include chain polysiloxanes (e.g., dimethylpolysiloxane, methylphenylpolysiloxane, diphenylpolysiloxane, etc.); cyclic polysiloxanes (e.g., octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, etc.); silicone resins forming a three-dimensional network structure; silicone rubber; various modified polysiloxanes (amino-modified polysiloxane, polyether-modified polysiloxane, alkyl-modified polysiloxane, fluorine-modified polysiloxane, etc.); and acrylic silicones.

[0100] Examples of amino acids include neutral amino acids such as glycine, alanine, valine, leucine, isoleucine, and aliphatic amino acids; oxyamino acids such as serine and threonine; aliphatic amino acids such as cysteine, cystine, and methionine, sulfur-containing amino acids such as glutamic acid and aspartic acid; amino acids having an amide group such as glutamine and asparagine; basic amino acids such as arginine; aromatic amino acids such as phenylalanine and tyrosine; and amino acids having an imino group such as proline and oxyproline.

[0101] The method for preparing a topical skin composition of the present invention is characterized by comprising the following process:

[0102] A process for growing crystals in an environment in which an aqueous solution (A) in which taurine is dissolved is mixed or contacted with a liquid substance (B) in which taurine is less soluble, wherein a useful component is dissolved or dispersed in the aqueous solution (A) or the liquid substance (B), and the useful component is included in the crystal as a result of crystal growth, and

[0103] A process of incorporating microneedle-shaped crystals of taurine containing useful components in the crystals, obtained from the above crystal growth process, into a topical skin preparation composition.

[0104] Individual topical skin compositions can be prepared by various manufacturing methods, such as maintaining the taurine concentration in the aqueous phase during the manufacturing process above the saturation concentration to prepare a formulation while retaining taurine microneedle crystals containing useful ingredients, or by incorporating taurine microneedle crystals containing useful ingredients obtained by separate recrystallization and then filtering and drying them. For details, refer to the formulation examples in the following examples.

[0105] Examples

[0106] The present invention will be explained in more detail below through the following examples. These examples are merely illustrative of the present invention and the scope of the present invention is not limited to these examples. Unless otherwise specified, the mixing amounts in the following examples are in mass%, and the units of thickness and length are micrometers.

[0107] Comparative Example 1

[0108] 100 mL of an aqueous solution containing 10% taurine and 0.1% cyanocobalamin was heated to 50°C and uniformly dissolved, then cooled to room temperature and left to stand for 24 hours. The precipitated crystals were separated by filtration and dried to obtain pink crystals.

[0109] Comparative Example 2

[0110] 100 mL of an aqueous solution containing 10% taurine, 0.1% cyanocobalamin, and 15 mL of ethanol was heated to 50°C and uniformly dissolved, then cooled to room temperature and left to stand for 24 hours. The precipitated crystals were separated by filtration and dried to obtain pink crystals.

[0111] Comparative Example 3

[0112] 100 mL of an aqueous solution containing 10% taurine, 5.0% nicotinamide, and 15 mL of ethanol was heated to 50°C and uniformly dissolved, then cooled to room temperature and left to stand for 24 hours. The precipitated crystals were separated by filtration and dried to obtain colorless, transparent crystals. The obtained crystals were analyzed by high-speed liquid chromatography to confirm that they contained nicotinamide.

[0113] Comparative Example 4

[0114] 100 mL of an aqueous solution containing 10% taurine, 5.0% nicotinamide, and 15 mL of ethanol was heated to 50°C and uniformly dissolved. Afterward, the solution was cooled to 30°C while stirring with a spatula, and the precipitated crystals were separated by filtration and dried to obtain colorless, transparent crystals. The obtained crystals were analyzed by high-speed liquid chromatography to confirm that they contained nicotinamide.

[0115] Comparative Example 5

[0116] 100 mL of an aqueous solution containing 10% taurine, 10% glycerin, and 0.0008% nicotinamide was heated to 50°C and uniformly dissolved, then cooled to 30°C while stirring, 15 mL of ethanol was slowly injected, and crystals precipitated at the interface separated into two phases were filtered, washed with ethanol, and dried. The obtained crystals were analyzed by high-speed liquid chromatography, and nicotinamide was not detected.

[0117] Comparative Example 6

[0118] 100 mL of an aqueous solution containing 2.5% taurine was heated to 50°C and uniformly dissolved, then cooled to 30°C while stirring, and after standing, 80 mL of an ethanol solution containing 5% nicotinamide was slowly injected, but no crystals were obtained.

[0119] Example 1

[0120] 100 mL of an aqueous solution containing 10% taurine and 0.1% cyanocobalamin was heated to 60°C and uniformly dissolved, then cooled to 30°C while stirring, and 15 mL of 1,3-butanediol was added while vigorously stirring with a disperser. The precipitated crystals were separated by filtration, washed with ethanol, and dried to obtain pink crystals.

[0121] Example 2

[0122] 100 mL of an aqueous solution containing 10% taurine and 10% glycerin was heated to 50°C and uniformly dissolved, then cooled to 30°C while stirring, and 15 mL of an ethanol solution containing 1.0% cyanocobalamin was added while vigorously stirring with a disperser, and the precipitated crystals were separated by filtration, washed with ethanol, and dried to obtain pink crystals.

[0123] Example 3

[0124] 100 mL of an aqueous solution containing 15% taurine was heated to 50°C and uniformly dissolved, then cooled to 40°C while stirring, and after standing, 15 mL of an ethanol solution containing 1% cyanocobalamin heated to 40°C was slowly injected, and the crystals precipitated at the interface separated into two phases were filtered and separated, washed with ethanol, and dried to obtain pink crystals.

[0125] Example 4

[0126] 100 mL of an aqueous solution containing 10% taurine was heated to 50°C and uniformly dissolved, then cooled to 30°C while stirring and left to stand. After standing, 15 mL of an ethanol solution containing 5% nicotinamide was slowly injected, and crystals precipitated at the interface separated into two phases were filtered and separated, washed with ethanol, and dried to obtain colorless, transparent crystals. The obtained crystals were analyzed by high-speed liquid chromatography to confirm that they contained nicotinamide.

[0127] Example 5

[0128] 100 mL of an aqueous solution containing 5% taurine was heated to 50°C and, after uniform dissolution, cooled to 30°C while stirring and set. Then, 15 mL of an ethanol solution containing 5% 3-O-ethylascorbic acid was slowly injected. Crystals precipitated at the interface separated into two phases were filtered and separated, washed with ethanol, and dried to obtain colorless, transparent crystals. The obtained crystals were analyzed by high-speed liquid chromatography to confirm that they contained 3-O-ethylascorbic acid.

[0129] Example 6

[0130] 100 mL of an aqueous solution containing 20% ​​taurine and 3% dipotassium glycyrrhizinate was heated to 70°C and uniformly dissolved, then cooled to 50°C while stirring and left to stand. Afterward, 15 mL of 1,3-propanediol heated to 50°C was slowly injected, and crystals precipitated at the interface separated into two phases were filtered and separated. After washing with a 50% aqueous ethanol solution, the crystals were dried to obtain colorless, transparent crystals. The obtained crystals were analyzed by high-speed liquid chromatography and confirmed to contain dipotassium glycyrrhizinate.

[0131] Example 7

[0132] 100 mL of an aqueous solution containing 8% taurine was heated to 50°C and uniformly dissolved, then cooled to 30°C while stirring and left to stand. After standing, 15 mL of an ethanol solution containing 5% L-ascorbic acid-2-glucoside was slowly injected, and crystals precipitated at the interface separated into two phases were filtered and separated, washed with ethanol, and dried to obtain colorless, transparent crystals. The obtained crystals were analyzed by high-speed liquid chromatography and confirmed to contain L-ascorbic acid-2-glucoside.

[0133] Example 8

[0134] 100 mL of an aqueous solution containing 25% taurine and 5% arbutin was heated to 80°C and, after homogeneous dissolution, allowed to stand. Then, 15 mL of 1,3-butylene glycol heated to 80°C was slowly injected, and crystals precipitated at the interface separated into two phases were filtered, washed with ethanol, and dried to obtain colorless, transparent crystals. The obtained crystals were analyzed by high-speed liquid chromatography to confirm that they contained arbutin.

[0135] Example 9

[0136] 100 mL of an aqueous solution containing 10% taurine was heated to 50°C and uniformly dissolved, then cooled to 30°C while stirring and left to stand. After standing, 15 mL of an ethanol solution containing 10% tetrahexyl decanoate ascorbyl was slowly injected, and crystals precipitated at the interface separated into two phases were filtered and separated, washed with ethanol, and dried to obtain colorless transparent crystals. The obtained crystals were analyzed by high-speed liquid chromatography and confirmed to contain tetrahexyl decanoate ascorbyl.

[0137] Example 10

[0138] 100 mL of an aqueous solution containing 15% taurine and 0.01% allantoin was heated to 60°C and uniformly dissolved, then cooled to 40°C while stirring, and after standing, 15 mL of ethanol was slowly injected. Crystals precipitated at the interface separated into two phases were filtered and separated, washed with a 50% aqueous ethanol solution, and dried to obtain colorless, transparent crystals. The obtained crystals were analyzed by high-speed liquid chromatography and confirmed to contain allantoin.

[0139] Example 11

[0140] 100 mL of an aqueous solution containing 12% taurine was heated to 50°C and uniformly dissolved, then cooled to 30°C while stirring and left to stand. After standing, 15 mL of an ethanol solution containing 0.1% tocopherol acetate was slowly injected, and crystals precipitated at the interface separated into two phases were filtered and separated, washed with ethanol, and dried to obtain colorless, transparent crystals. The obtained crystals were analyzed by high-speed liquid chromatography and confirmed to contain tocopherol acetate.

[0141] Example 12

[0142] 100 mL of an aqueous solution containing 10% taurine and 0.5% copper chlorophyllin sodium was heated to 50°C and uniformly dissolved, then cooled to 30°C while stirring, and after standing, 15 mL of ethanol was slowly injected, and the crystals precipitated at the interface separated into two phases were filtered and separated, washed with a 50% ethanol aqueous solution, and dried to obtain green crystals.

[0143] Example 13

[0144] 100 mL of an aqueous solution containing 10% taurine and 1% gardenia extract was heated to 50°C and uniformly dissolved, then cooled to 30°C while stirring, and after standing, 15 mL of ethanol was slowly injected, and the crystals precipitated at the interface separated into two phases were filtered and separated, washed with a 50% ethanol aqueous solution, and dried to obtain a blue crystalline product.

[0145] Example 14

[0146] 100 mL of an aqueous solution containing 12% taurine was heated to 50°C and uniformly dissolved, then cooled to 35°C while stirring, and after standing, 15 mL of an ethanol solution containing 5% ubidecarenone heated to 40°C was slowly injected, and crystals precipitated at the interface separated into two phases were filtered and separated, washed with ethanol heated to 40°C, and dried to obtain pale yellow needle-shaped crystals containing ubidecarenone.

[0147] Example 15

[0148] 100 mL of an aqueous solution containing 10% taurine was heated to 50°C and uniformly dissolved, then cooled to 35°C while stirring, and after standing, 15 mL of an ethanol solution containing 3% β-carotene suspension (β-carotene 30% suspension: DSM Co., Ltd.) was slowly injected, and crystals precipitated at the interface separated into two phases were filtered and separated, washed with ethanol heated to 40°C, and dried to obtain needle-shaped crystals of pale color containing β-carotene.

[0149] Example 16

[0150] 100 mL of an aqueous solution containing 8% taurine was heated to 50°C and uniformly dissolved, then cooled to 35°C while stirring, and after standing, 15 mL of an ethanol solution containing 3% astaxanthin solution (astaxanthin-5C: Oryza Yuka Co., Ltd.) was slowly injected, and crystals precipitated at the interface separated into two phases were filtered and separated, washed with ethanol heated to 40°C, and dried to obtain orange needle-shaped crystals containing astaxanthin.

[0151] Microscopic observation of the crystals obtained in Comparative Examples 1 to 5 and Examples 1 to 16 was performed. The crystal shape, crystal thickness, and crystal length were confirmed. Subsequently, the feel of each crystal when combined with the liquid formulation shown in Table 1 and the cosmetic emulsion formulation shown in Table 2 was evaluated using the ratings listed in Table 3. The results are shown in Tables 4 to 6.

[0152] Regarding the emulsion, the concentration of taurine in phase A was set to a saturated concentration at 25°C, phase B was added to phase A heated to 80°C while mixing with a homomixer, and after cooling to 25°C, phase C was mixed, and a taurine crystal of layer D was mixed into the obtained composition to prepare an emulsion containing crystals.

[0153] For the cosmetic emulsion, phase A was heated to 100°C and mixed, then cooled to 25°C, and the taurine crystals of phase B were mixed to prepare a cosmetic emulsion containing crystals.

[0154]

[0155]

[0156]

[0157]

[0158]

[0159]

[0160] As shown in Tables 4 to 6, the crystals obtained in the manufacturing method of the present invention form fine needle-shaped or columnar crystals, and it was confirmed that by controlling the crystal size, the texture of the compound has no roughness and the texture is clearly improved.

[0161] Example 17

[0162] 100 mL of an aqueous solution containing 10 mass% taurine and 10 mass% glycerin was heated to 50°C and uniformly dissolved, then cooled to 40°C while stirring and left to stand. After standing, 15 mL of an ethanol solution containing 5 mass% uranine (a fluorescent substance) heated to 40°C was slowly injected. Crystals precipitated at the interface separated into two phases were filtered and separated, washed with ethanol, and dried to obtain orange-yellow crystals. Microscopic images of the obtained crystals are shown in Figures 4 to 7.

[0163] As shown in FIGS. 4 to 7, the shape of the obtained taurine microcrystals was needle-shaped. The micro needle-shaped crystals had a maximum thickness of 30 micrometers and a maximum length of 230 micrometers.

[0164] As shown in Figures 5 and 7, the obtained crystals were observed under a fluorescence microscope, and it was confirmed that uranine was contained within the crystals.

[0165] Example 18

[0166] The following composition was prepared by combining the crystals obtained in Example 17, and the penetration of the inclusion component into the skin was evaluated.

[0167] [Composition]

[0168] [A]

[0169] 81.60 mass% purified water

[0170] Taurine 8.00 mass%

[0171] Carboxyvinyl polymer 0.20 mass%

[0172] [B]

[0173] Arginine 0.20 mass%

[0174] [C]

[0175] 10.0 mass% of fine needle-shaped crystals obtained in Example 17

[0176] Phase A, which was uniformly dissolved by heating to 80°C and cooling to 35°C, was added while stirring, and stirred at 35°C for 10 minutes. Phase C was then added and stirred for 10 minutes to achieve a uniform mixture, thereby obtaining an aqueous gel composition.

[0177] The obtained composition was applied to human excised skin (thickness 700 micrometers) (provided by the U.S. Tissue Bank), and fluorescence observation of the skin cross-section was performed after 5 minutes, and it was confirmed that microneedle-shaped crystals containing uranine were punctured and reached the stratum corneum, epidermis, and dermis (Fig. 8).

[0178] Additionally, when observing the condition after 30 minutes, it was confirmed that the crystal pierced in the skin had dissolved and uranine had diffused into the skin (Fig. 9).

[0179] Example 19 and Comparative Example 7

[0180] Microneedle-shaped crystals containing dipotassium glycyrrhizinate were prepared, and the amount of dipotassium glycyrrhizinate penetrating into the skin was measured.

[0181] 100 mL of an aqueous solution containing 10 mass% taurine and 3 mass% dipotassium glycyrrhizinate was heated to 60°C and uniformly dissolved, then cooled to 40°C while stirring, and after standing, 15 mL of ethanol was slowly injected, and the crystals precipitated at the interface separated into two phases were filtered and separated, washed with ethanol, and dried to obtain a crystal product.

[0182] The shape of the obtained taurine microcrystals was needle-like. The needle-like microcrystals had a maximum thickness of 30 micrometers and a maximum length of 180 micrometers.

[0183] In addition, the obtained crystals were analyzed by liquid chromatography and it was confirmed that they contained 0.101 mass% of dipotassium glycyrrhizinate.

[0184] A composition of the table below containing 10 mass% of this fine needle-shaped crystal, and a composition of a comparative example in which dipotassium glycyrrhizinate was dissolved to the same concentration as this were prepared, and the amount of dipotassium glycyrrhizinate penetrating into the skin was compared when the obtained composition was applied to human skin.

[0185]

[0186] To evaluate the amount of penetration into the skin, each sample was applied to human excised skin at a rate of 10.0 mg / square centimeter using a vertical Franz-type diffusion cell with an effective diameter of 2.0 centimeters, an area of ​​3.14 square centimeters, and a receptor solution volume of 2.4 mL.

[0187] After 6 hours, the stratum corneum and the epidermis and dermis were separated from the sample skin by tape stripping, and the dipotassium glycyrrhizinate contained in each of the stratum corneum, epidermis and dermis, and receptor solution was quantified by high-speed liquid chromatography.

[0188] As shown in FIG. 10, regarding the composition of Example 19, compared to the composition of Comparative Example 7, the penetration amount of dipotassium glycyrrhizinate throughout the skin is about 2.5 times, and it was confirmed that by incorporating the useful component into the microacoustic crystals, the useful component penetrates the epidermis, dermis, and receptor solution.

[0189] Examples of prescriptions are provided below, but the present invention is not limited to these examples.

[0190] 〔toilet water〕

[0191] [A]

[0192] 71.60 mass% purified water

[0193] Taurine 7.80 mass%

[0194] Glycerin 5.00 mass%

[0195] Diglycerin 0.50 mass%

[0196] Betaine 0.50 mass%

[0197] Phenoxyethanol 0.30 mass%

[0198] [B]

[0199] Dipropylene glycol 10.00 mass%

[0200] 1,2-Pentanediol 2.50 mass%

[0201] [C]

[0202] (Acrylate / Methacrylic Acid Steareless-20) Copolymer

[0203] 0.45 mass%

[0204] 1.05 mass% purified water

[0205] [D]

[0206] 0.30 mass% of the crystal obtained in Example 1

[0207] Phase A, which was heated to 80°C and uniformly dissolved, was cooled to 35°C, added to Phase B while stirring, and stirred at 35°C for 10 minutes. Phase C was added thereto and uniformly mixed by stirring with a homomixer for 10 minutes, then crystals of Phase D were added and stirred for 5 minutes to obtain a cosmetic water composition.

[0208] The shape of the taurine microcrystals in the obtained composition is needle-shaped, with a maximum thickness of 30 micrometers and a maximum length of 300 micrometers, and the composition has a smooth feel and good usability.

[0209] [Aqueous Gel]

[0210] [A]

[0211] 71.40 mass% purified water

[0212] Taurine 8.00 mass%

[0213] Glycerin 5.00 mass%

[0214] Raffinose 0.50 mass%

[0215] Phenoxyethanol 0.30 mass%

[0216] [B]

[0217] Dipropylene glycol 10.00 mass%

[0218] 1,2-Pentanediol 2.50 mass%

[0219] [C]

[0220] Polyacrylate crosspolymer-6 2.00 mass%

[0221] [D]

[0222] 0.30 mass% of the crystals obtained in Example 14

[0223] Phase A, which was uniformly dissolved by heating to 80°C, was cooled to 35°C and added to Phase B while stirring. The mixture was stirred at 35°C for 10 minutes to precipitate fine needle-shaped crystals of taurine. Phase C was added to this mixture and homogenized by stirring with a homomixer for 10 minutes. Then, crystals of Phase D were added and stirred for 5 minutes to obtain an aqueous gel composition.

[0224] The shape of the taurine microcrystals in the obtained composition was needle-shaped, with a maximum thickness of 30 micrometers and a maximum length of 230 micrometers. The obtained composition had a smooth feel and a good feel when used.

[0225] 〔latex〕

[0226] [A]

[0227] 60.20 mass% purified water

[0228] Taurine 8.00 mass%

[0229] Glycerin 5.00 mass%

[0230] [B]

[0231] 1,3-Propanediol 15.00 mass%

[0232] 3-O-ethylascorbic acid 3.00 mass%

[0233] Pentylene glycol 1.50 mass%

[0234] Phenoxyethanol 0.30 mass%

[0235] [C]

[0236] (hydroxyethyl acrylate / acryloyldimethyltaurine sodium)copolymer

[0237] 0.75 mass%

[0238] Isohexadecane 0.45 mass%

[0239] Polysorbate 80 0.15 mass%

[0240] 0.65 mass% purified water

[0241] [D]

[0242] Squalane 5.00 mass%

[0243] Phase A, which was heated to 80°C and uniformly dissolved, was cooled to 35°C and added to Phase B while stirring. The mixture was stirred at 35°C for 10 minutes to precipitate fine needle-shaped crystals of taurine. A mixture of Phase C was added to this, and after uniform mixing by stirring with a homomixer for 5 minutes, Phase D was added and emulsified by stirring with a homomixer for 10 minutes to obtain an emulsion composition.

[0244] The shape of the taurine microcrystals in the obtained composition is needle-shaped, with a maximum thickness of 30 micrometers and a maximum length of 250 micrometers, and it was confirmed by high-speed liquid chromatography analysis that 3-O-ethylascorbic acid is contained. The obtained composition has a smooth feel and a good feel when used.

[0245] [O / W type cream]

[0246] [A]

[0247] 63.00 mass% purified water

[0248] Taurine 8.00 mass%

[0249] Glycerin 5.00 mass%

[0250] Nicotinamide 5.00 mass%

[0251] [B]

[0252] 1,3-Propanediol 15.00 mass%

[0253] Pentylene glycol 1.50 mass%

[0254] Phenoxyethanol 0.30 mass%

[0255] [C]

[0256] (hydroxyethyl acrylate / acryloyldimethyltaurine Na)copolymer

[0257] 0.75 mass%

[0258] Polysorbate 80 0.15 mass%

[0259] 0.65 mass% purified water

[0260] [D]

[0261] Squalane 0.65 mass%

[0262] Phase A, which was heated to 80°C and uniformly dissolved, was cooled to 35°C and added to Phase B while stirring. The mixture was stirred at 35°C for 10 minutes to precipitate fine needle-shaped crystals of taurine. A mixture of Phase C was added to this, and after uniform mixing by stirring with a homomixer for 5 minutes, Phase D was added and emulsified by stirring with a homomixer for 10 minutes to obtain an O / W type cream composition.

[0263] The shape of the taurine microcrystals in the obtained composition is needle-shaped, with a maximum thickness of 30 micrometers and a maximum length of 250 micrometers, and it was confirmed by high-speed liquid chromatography analysis that nicotinamide is contained. The obtained composition has a smooth feel and a good feel when used.

[0264] [W / O Cream]

[0265] [A]

[0266] 32.30 mass% purified water

[0267] Taurine 7.00 mass%

[0268] Glycerin 5.00 mass%

[0269] L-ascorbic acid-2-glucoside 2.00 mass%

[0270] [B]

[0271] 1,3-Propanediol 9.00 mass%

[0272] 1,2-Hexanediol 0.70 mass%

[0273] Phenoxyethanol 0.30 mass%

[0274] [C]

[0275] Isopropyl myristate 33.70 mass%

[0276] Jojoba oil 5.00 mass%

[0277] Polyricinoleic acid polyglyceryl-6 3.25 mass%

[0278] Polyglyceryl-2 isostearic acid 1.00 mass%

[0279] Distearidimonium hectorite 0.75 mass%

[0280] Phase A, which was heated to 80°C and uniformly dissolved, was cooled to 35°C and added to Phase B while stirring. The mixture was stirred at 35°C for 10 minutes to precipitate fine needle-shaped crystals of taurine. This mixture was added to Phase C, which was uniformly mixed, over a period of 5 minutes using a homomixer, and then emulsified by stirring with a homomixer for 10 minutes to obtain a W / O type cream composition.

[0281] Among the obtained compositions, the shape of the taurine microcrystals is needle-shaped, with a maximum thickness of 25 micrometers and a maximum length of 200 micrometers, and it was confirmed by high-speed liquid chromatography analysis that L-ascorbic acid-2-glucoside is contained. The obtained composition has a smooth feel when used, and a composition with good usability was obtained.

[0282] [Cosmetic Oil]

[0283] [A]

[0284] 2-Cetyl ethylhexanoate 63.40 mass%

[0285] Hydrogenated polydecene 29.00 mass%

[0286] Hydrogenated (styrene / isoprene) copolymer 7.00 mass%

[0287] Tocopherol 0.10 mass%

[0288] [B]

[0289] 0.50 mass% of taurine microneedle crystals obtained in Example 11

[0290] Phase A was heated to 100°C and stirred until homogeneous. This was cooled to 35°C, Phase B was added, and stirred to disperse uniformly, thereby obtaining a cosmetic oil composition.

[0291] The shape of the taurine microcrystals in the obtained composition was needle-shaped, with a maximum thickness of 40 micrometers and a maximum length of 520 micrometers. The obtained composition had a smooth feel and a good feel when used.

[0292] Test Example 1

[0293] In the taurine containing various beneficial components prepared above, a test was conducted to demonstrate that the beneficial components are contained within the taurine crystals. The following is the result of X-ray diffraction of the astaxanthin-containing taurine needle crystals prepared in Example 14.

[0294] As a control, needle-shaped crystals of taurine alone were prepared by the following process.

[0295] 100 mL of an aqueous solution containing 10% taurine was heated to 50°C and uniformly dissolved, then cooled to 30°C while stirring, and after standing, 15 mL of ethanol was slowly injected. Crystals precipitated at the interface separated into two phases were filtered and separated, washed with ethanol, and dried to obtain colorless transparent crystals.

[0296] X-ray diffraction of taurine needle crystals and astaxanthin-containing taurine needle crystals was performed using an X-ray diffraction device, model number SmartLab, manufactured by Rigaku Co., Ltd. X-rays (wavelength = 0.154 nm), with an output of 45 kV and 200 mA, and a HyPix-3000 detector, measurements were performed using the 2θ / θ measurement method with a scanning speed of 10° / min for a range of 2θ from 10 to 80°.

[0297] The obtained X-ray diffraction pattern is shown in Fig. 1. The top is the astaxanthin-containing taurine crystal, and the bottom is the diffraction pattern from the taurine crystal.

[0298] From the above results, astaxanthin-containing taurine crystals and taurine crystals do not exhibit the same diffraction pattern. The diffraction angles of the 111th and 200th planes are summarized in Table 8 below. Specifically, the lattice constants were calculated from the following data using Bragg's equation for the spread of the 111th and 200th planes (a decrease in 2θ indicates a spread of the plane spacing).

[0299]

[0300] An example of an optical microscope image of a crystal obtained by the present invention is shown in FIG. 2. This crystal was obtained by Example 3. An example of a crystal microscope image of raw material taurine is shown in FIG. 3. The raw material taurine used was Japanese Pharmacopoeia taurine (manufactured by Shoka Akuhin Co., Ltd.).

Claims

Claim 1 A skin external use composition characterized by containing microneedle-shaped crystals of taurine containing or supporting skin-beneficial ingredients within the crystals, wherein the thickness of the microneedle-shaped crystals of taurine is 150 micrometers or less and the length is 3000 micrometers or less. Claim 2 A topical skin composition according to claim 1, characterized in that at least some of the fine needle-shaped crystals of taurine are dispersed therein. Claim 3 A skin external application composition according to claim 1 or 2, characterized in that it has a space inside the microacicular crystals of taurine, and a skin-beneficial ingredient is contained within the said space. Claim 4 A topical skin composition according to claim 3, characterized in that the internal space volume of the microacicular crystals of taurine occupies 0.001% to 30% of the volume of the taurine crystals. Claim 5 A skin external preparation composition according to claim 1 or 2, characterized in that the skin beneficial ingredient is one or more selected from the group consisting of vitamins and vitamin derivatives, hydroquinone and its derivatives, whitening ingredients, anti-inflammatory ingredients, antioxidant ingredients, blood circulation promoting ingredients, cell revitalization ingredients, coenzymes and their intermediate metabolites, sugars, plant extract ingredients, peptides, proteins, and pigments. Claim 6 A skin external preparation composition according to claim 1 or 2, characterized in that the inclusion rate of the skin-beneficial component in the microacicular crystals of taurine is 0.001% to 30%. Claim 7 A skin external use composition according to claim 1 or 2, wherein, additionally, a skin-beneficial ingredient is dissolved or dispersed within the skin external use composition medium. Claim 8 A method for manufacturing microneedle crystals of taurine containing or supporting a skin-beneficial component in a crystal, comprising a process of growing crystals in an environment in which an aqueous solution (A) in which taurine is dissolved is mixed or contacted with a liquid substance (B) in which taurine has low solubility, wherein the skin-beneficial component is dissolved or dispersed in the aqueous solution (A) or the liquid substance (B), and the skin-beneficial component is included in the crystal as the crystal grows, wherein the thickness of the microneedle crystals of taurine is 150 micrometers or less and the length is 3000 micrometers or less. Claim 9 A method of manufacturing according to claim 8, characterized in that the liquid substance (B) is a water-soluble organic solvent. Claim 10 A method of manufacturing according to claim 9, wherein the water-soluble organic solvent is one or more selected from the group consisting of ethanol, isopropyl alcohol, ethylene glycol, 1,2-propanediol, 1,3-propanediol, 1,2-butanediol, 1,3-butanediol, isoprene glycol, diethylene glycol, dipropylene glycol, glycerin, diglycerin, 1,2-pentanediol, 1,2-hexanediol, cyclohexylglycerin, and n-hexylglycerin. Claim 11 A method of manufacturing, characterized in that, in any one of claims 8 to 10, the concentration of the skin-beneficial ingredient is 0.001 mass% or more in the aqueous solution (A) or in the liquid substance (B). Claim 12 A method of manufacturing, characterized in that, in any one of claims 8 to 10, the concentration of taurine in the aqueous solution (A) is 3 to 28 mass%. Claim 13 A method of manufacturing, characterized in that, in any one of claims 8 to 10, the liquid substance (B) is 50 mass% or less with respect to the total amount of the aqueous solution (A). Claim 14 A method for preparing a topical skin preparation composition containing microneedle crystals of taurine containing or supporting a skin-beneficial ingredient within the crystal, comprising the following steps: a process of growing crystals in an environment in which an aqueous solution (A) in which taurine is dissolved is mixed or contacted with a liquid substance (B) in which taurine has low solubility, wherein the skin-beneficial ingredient is dissolved or dispersed in the aqueous solution (A) or the liquid substance (B), and thereby the skin-beneficial ingredient is included in the crystals as the crystals grow, and a process of incorporating microneedle crystals of taurine containing or supporting a skin-beneficial ingredient within the crystals obtained in the crystal-growing process into the topical skin preparation composition, wherein the thickness of the microneedle crystals of taurine is 150 micrometers or less and the length is 3000 micrometers or less. Claim 15 A method of manufacturing according to claim 14, characterized in that the concentration of the skin-beneficial ingredient is 0.001 mass% or more in the aqueous solution (A) or the liquid substance (B). Claim 16 A method of manufacturing according to claim 14 or 15, characterized in that the concentration of taurine in the aqueous solution (A) is 3 to 28 mass%. Claim 17 A method of manufacturing according to claim 14 or 15, characterized in that the liquid substance (B) is 50 mass% or less with respect to the total amount of the aqueous solution (A). Claim 18 A method of manufacturing according to claim 14 or 15, wherein the liquid substance (B) is a water-soluble organic solvent, and the water-soluble organic solvent is one or more selected from the group consisting of ethanol, isopropyl alcohol, ethylene glycol, 1,2-propanediol, 1,3-propanediol, 1,2-butanediol, 1,3-butanediol, isoprene glycol, diethylene glycol, dipropylene glycol, glycerin, diglycerin, 1,2-pentanediol, 1,2-hexanediol, cyclohexylglycerin, and n-hexylglycerin. Claim 19 delete

Images